CJC / IPA Blend
SKU：cjc-ipa-blend
Price：USD 60.00
Product information
This blend pairs CJC-1295 with ipamorelin for growth-hormone-axis research. A GHRH-related signal and a separate growth-hormone-secretagogue-receptor pathway, GHS-R, provide different experimental targets. Research compares exposure to both ingredients with exposure to either ingredient alone. That comparative design does not establish that the complete formulation produces a validated clinical outcome.
Product specifications
- Strength
- 10mg
- Molecular Formula
- BLEND
- Molecular Weight
- N/A (Blend)
- Purity
- >99% (HPLC)
- Form
- Lyophilized Powder
- Blend Components
- CJC-1295 (Modified GRF 1-29) + Ipamorelin
- CJC-1295 Type
- GHRH analog - GHRH-R agonist (no DAC modification)
- Ipamorelin Type
- Pentapeptide GH secretagogue - GHSR-1a agonist
- CJC-1295 MW
- 3,367.9 g/mol
- Ipamorelin MW
- 711.9 g/mol
- CJC Half-Life
- ~20-30 minutes
- Ipamorelin Half-Life
- ~2 hours
- Form
- Lyophilized powder (co-lyophilized blend)
- Purity
- ≥99% each component (HPLC verified)
- Testing
- Third-party HPLC, Mass Spec, Endotoxin
- Storage
- -20°C for up to 24 months
- Solubility
- Water-soluble
- Appearance
- White to off-white powder
Analysis report
CJC-1295 5 mg/IPA 5mg · 10mg · CJC-091126-10
CJC-1295 5mg NO DAC + Ipamorelin 5mg · 5mg · H2XMF1
CJC-1295 5mg NO DAC + Ipamorelin 5mg · 5mg · 7Q086C
CJC-1295 5mg NO DAC + Ipamorelin 5mg · 5mg · 78WS7U
CJC-1295 (no dac) 5mg + · 5mg · 1100001
Ipamorelin · Not provided · IPCJ12092025-J
Research information
Read the full CJC / IPA Blend research monograph
Research overview
This blend pairs CJC-1295 with ipamorelin for growth-hormone-axis research. A GHRH-related signal and a separate growth-hormone-secretagogue-receptor pathway, GHS-R, provide different experimental targets. Research compares exposure to both ingredients with exposure to either ingredient alone. That comparative design does not establish that the complete formulation produces a validated clinical outcome.